Citations (16)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Qi-Zhu Feng, Xian-Zhi Chen, Jie Sun, Man-Man Lu, Yong Wang, Qi Wang & Chao Zhang. (2021) Analysis of the Effect of Trastuzumab Combined with Docetaxel on Serum Tumor Markers in the Treatment of HER-2 Positive Breast Cancer and Factors Influencing Therapeutic Efficacy. Cancer Management and Research 13, pages 8077-8084.
Read now
Read now
Nour Hisham Al-Ziftawi, Asrul Akmal Shafie & Mohamed Izham Mohamed Ibrahim. (2021) Cost-effectiveness analyses of breast cancer medications use in developing countries: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 21:4, pages 655-666.
Read now
Read now
Giorgio Mustacchi. (2021) Cost/benefit evaluations in low-middle/upper-middle income countries: biases about “out of pocket money”. Current Medical Research and Opinion 37:5, pages 819-820.
Read now
Read now
Rita De Santis. (2020) Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy. mAbs 12:1.
Read now
Read now
Articles from other publishers (12)
Yang Li, Jingjiao Zhang, Zhengang Cai, Xue Gao, Lina Zhang, Zhi Lu, Xiaojie Wang, Peiyao Yu, Jia Li & Fengqi Fang. (2023) Disitamab Vedotin (RC48) for HER2-positive advanced breast cancer: a case report and literature review. Frontiers in Oncology 13.
Crossref
Crossref
Lenka Šlegerová & Kateřina Kopečková. (2023) The Cost-Effectiveness of Pertuzumab for the Treatment of Metastatic HER2+ Breast Cancer in Czechia: A Semi-Markov Model Using Cost States. Value in Health Regional Issues 38, pages 118-125.
Crossref
Crossref
Paula Medeiros do Valle, Cid Manso de Mello Vianna, Gabriela Bittencourt Gonzalez Mosegui, Idoaldo José de Lima, Magda Conceição Gomes Falcão Leal & Fabiano Saldanha Gomes de Oliveira. (2023) Using the analytic hierarchy process to elicit patient preference in the evaluation of first-line treatment of HER2-overexpressing metastatic breast cancer. Cadernos Saúde Coletiva 31:1.
Crossref
Crossref
John Hang Leung, Yun-sheng Tai, Shyh-Yau Wang, Hei-Tung Yip Fion, Ho Tsung-chin & Agnes LF. Chan. (2022) Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer. The Breast 65, pages 91-97.
Crossref
Crossref
Wei Fang Dai, Jaclyn M. Beca, Chenthila Nagamuthu, Ning Liu, Claire de Oliveira, Craig C. Earle, Maureen Trudeau & Kelvin K. W. Chan. (2022) Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer. JAMA Oncology 8:4, pages 597.
Crossref
Crossref
Kensuke Moriwaki, Saki Uechi, Takaaki Fujiwara, Yu Hagino & Kojiro Shimozuma. (2021) Economic Evaluation of First-Line Pertuzumab Therapy in Patients with HER2-Positive Metastatic Breast Cancer in Japan. PharmacoEconomics - Open 5:3, pages 437-447.
Crossref
Crossref
Tsung-Ying Lee, Hsuan-Ying Chen, Tsai-Yun Chen, Sin-Syue Li, Wei-Tse Fang, Yao-Chun Wen, Yu-Wen Lo & Huang-Tz Ou. (2020) Cost-utility analysis of inotuzumab ozogamicin for relapsed or refractory B cell acute lymphoblastic leukemia from the perspective of Taiwan’s health care system. The European Journal of Health Economics 21:7, pages 1105-1116.
Crossref
Crossref
Vakaramoko Diaby, Hussain Alqhtani, Sascha van Boemmel-Wegmann, Ching-Yu Wang, Askal Ayalew Ali, Rajesh Balkrishnan, Yu Ko, Sofia Palacio & Gilberto de Lima Lopes. (2020) A cost-effectiveness analysis of trastuzumab-containing treatment sequences for HER-2 positive metastatic breast cancer patients in Taiwan. The Breast 49, pages 141-148.
Crossref
Crossref
Atefeh Arab, Rezvan Yazdian-Robati & Javad Behravan. (2020) HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development. Archivum Immunologiae et Therapiae Experimentalis 68:1.
Crossref
Crossref
Aaron P. Mitchell, Alan C. Kinlaw, Sharon Peacock-Hinton, Stacie B. Dusetzina, Hanna K. Sanoff & Jennifer L. Lund. (2020) Use of High-Cost Cancer Treatments in Academic and Nonacademic Practice. The Oncologist 25:1, pages 46-54.
Crossref
Crossref
Louis P. GarrisonJr.Jr., Joseph Babigumira, Clément Tournier, Hans-Peter Goertz, Solomon J. Lubinga & Edith A. Perez. (2019) Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States. Value in Health 22:4, pages 408-415.
Crossref
Crossref
Anagha Gogate, Jason S. Rotter, Justin G. Trogdon, Ke Meng, Christopher D. Baggett, Katherine E. Reeder-Hayes & Stephanie B. Wheeler. (2019) An updated systematic review of the cost-effectiveness of therapies for metastatic breast cancer. Breast Cancer Research and Treatment 174:2, pages 343-355.
Crossref
Crossref